ACOMS+ 및 학술지 리포지터리 설명회

  • 한국과학기술정보연구원(KISTI) 서울분원 대회의실(별관 3층)
  • 2024년 07월 03일(수) 13:30
 

논문 상세

Home > 논문 상세
  • P-ISSN 1010-0695
  • E-ISSN 2288-3339

Antitumor Effects of Water Extracts of Panax notoginseng on NCI-H460 Tumor Regression Model

대한한의학회지 / Journal of Korean Medicine, (P)1010-0695; (E)2288-3339
2010, v.31 no.3, pp.8-16
Seung-Chan Park (Daejeon University)
Tae-Young Jeong (Daejeon University)
조종관 (대전대학교)
이연월 (대전대학교)
유화승 (Daejeon University)
  • 다운로드 수
  • 조회수

Abstract

Objective: This study aimed to investigate the antitumor effects of water extracts of Panax notoginseng (WEPN) in NCI-H460 human lung cancer cell xenografted nude mice. Materials and Methods: We cultured NCI-H460 cell lines and xenografted them to nude mice. The mice were divided into 3 groups; positive control group, NCI-H460+150 ㎎/㎏ WEPN-treated group, and NCI-H460+300 ㎎/㎏ WEPN-treated group. They had been raised and treated in 28 days. We checked their body weight and tumor weight and volumes twice a week and their absolute organ weight and microhistological observation at the final day. We also calculated their tumor inhibition rate (I.R.), mean survival time and percent increase in life span (% ILS). Results: Body weight of WEPN (300 ㎎/㎏) treated mice tended to slightly greater increase than those of the positive control group, but had no significance. Tumor volume (measurement with a caliper) of WEPN-treated mice tended to be lower than that of the positive control group. Inhibition rate (I.R.) of the WEPN group decreased more than the positive control group, but had no significance. Results of tumor weights and volume (plethysmography) had no significance. Mean survival time and percent increase in life span (% ILS) in the WEPN 300 ㎎/㎏ treatment group were higher than those of any other group (p<0.05). In absolute organ weights, the WEPN (150-300 ㎎/㎏) treatment group decreased liver weights (p<0.05). Liver tissue of mice treated with WEPN (300 ㎎/㎏) did not show any specific lesions. Conclusion: We suggest that WEPN may have potential as a growth inhibitor of solid tumors induced by NCI-H460 without any side effects. However, this study has limitations in proving anti-tumor effects of WEPN, so further studies to overcome those limitations will be needed.

keywords
Panax notoginseng, NCI-H460, lung cancer, antitumor, in vivo


참고문헌

1

1 Harkey MR, Henderson GL, Gershwin ME, Stern JS, Hackman RM. Variability in commercial ginseng products: an analysis of 25 preparations. Am J Clin Nutr. 2001; 73(6):1101-6.

2

2 Ng TB. Pharmacological activity of sanchi ginseng (Panax notoginseng). J Pharm Pharmacol. 2006; 58(8):1007-19.

3

3 Ji W, Gong BQ. Hypolipidemic effects and mechanisms of Panax notoginseng on lipid profile in hyperlipidemic rats. J Ethnopharmacol. 2007; 113(2):318-24.

4

4 Hu LY, Fan YP. Review of study on the mechanism of active ingredients of single Chinese drug in treating intracerebral hemorrhage. Zhongguo Zhong Xi Yi Jie He Za Zhi. 2006; 26(4):376-80.

5

5 Park WH, Lee SK, Kim CH. A Korean herbal medicine, Panax notoginseng, prevents liver fibrosis and hepatic microvascular dysfunction in rats. Life Sci. 2005; 76(15):1675-90.

6

6 Lin CF, Wong KL, Wu RS, Huang TC, Liu CF. Protection by hot water extract of Panax notoginseng on chronic ethanol-induced hepatotoxicity. Phytother Res. 2003; 17(9):1119-22.

7

7 Yang XG, Lu B, Guo Y. A review of adverse effects of Panax notoginseng (Burk.) F.H.Chen. Zhong Yao Cai. 2002; 25(3):216-8.

8

8 Konoshima T, Takasaki M, Tokuda H. Anticarcinogenic activity of the roots of Panax notoginseng. Biol Pharm Bull. 1999; 22(10):1150-2.

9

9 Li Z, He C, Wang C, Cui X, Yu S, Luo W. Studies on control of root rot on Panax notoginseng. Zhong Yao Cai. 1998; 21(4):163-6.

10

10 Yang ZG, Sun HX, Ye YP. Ginsenoside Rd from Panax notoginseng is cytotoxic towards HeLa cancer cells and induces apoptosis. Chem Biodivers. 2006; 3(2):187-97.

11

11 Wang CZ, Xie JT, Zhang B, Ni M, Fishbein A, Aung HH, et al. Chemopreventive effects of Panax notoginseng and its major constituents on SW480 human colorectal cancer cells. Int J Oncol. 2007; 31(5):1149-56.

12

12 Wang W, Wang H, Rayburn ER, Zhao Y, Hill DL, Zhang R. 20(S)-25-methoxyl-dammarane- 3beta, 12beta, 20-triol, a novel natural product for prostate cancer therapy: activity in vitro and in vivo and mechanisms of action. Br J Cancer. 2008; 98(4):792-802.

13

13 Lei Y, Gao Q, Chen KJ. Effects of extracts from Panax notoginseng and Panax ginseng fruit on vascular endothelial cell proliferation and migration in vitro. Chin J Integr Med. 2008; 14(1):37-41.

14

14 Yan ZC, Chen D, Wu XZ, Xie GR, Ba Y, Yan Z. Effects of aqueous extracts of Aconitum carmichaeli, Rhizoma bolbostemmatis, Phytolacca acinosa, Panax notoginseng and Gekko swinhonis G?enther on Bel-7402 cells. World J Gastroenterol. 2007; 13(19):2743-6.

15

15 Hai J, Lin Q, Lu Y, Zhang H, Yi J. Induction of apoptosis in rat C6 glioma cells by panaxydol. Cell Biol Int. 2007; 31(7):711-5.

16

16 Chen PF, Liu LM, Chen Z, Lin SY, Song WX, Xu YF. Effects of ethanol extracts of Panax notoginseng on liver metastasis of B16 melanoma grafted in mice. Zhong Xi Yi Jie He Xue Bao. 2006; 4(5):500-3.

17

17 Kim HM, Lim J, Park SK, Kang JS, Lee K, Lee CW, et al. Antitumor activity of cytokine-induced killer cells against human lung cancer. International Immunopharmacology 2007; 7(13):1802-7.

18

18 Chai HY, Sin JS, Kim TM, Kwon W, Cho YM, Choi EK, et al. Antitumor Activity of K6, an allylthiopyridazine derivative, in Hep-$G_{2}$ cellstransplanted nude mice. Kor. J. of Lab Ani Sci 2004; 20(1):1-10.

19

19 Teicher BA. Anticancer Drug Development Guide. Humana Press, New Jersey. 1997; 91-7.

20

20 Yang EB, Tang WY, Zhang K, Cheng LY, Mack POP. Norcantharidin inhibits growth of human HepG2 cell-transplanted tumor in nude mice and prolongs host survival. Cancer Lett 1997; 117(1):93-8.

21

21 Chung VQ, Tattersall M, Cheung HT. Interactions of a herbal combination that inhibits growth of prostate cancer cells. Cancer Chemother Pharmacol. 2004; 53(5):384-90.

22

22 Langdon SP, Hendriks HR, Braakhuis BJ, Pratesi G, Berger DP, Fodstad O, et al. Preclinical phase II studies in human tumor xenografts: a European multicenter follow-up study. Ann Oncol. 1994; 5(5):415-22.

상단으로 이동

대한한의학회지